[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-335138-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-335138-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","cdk46-inhibitors-plus-endocrine-therapy-vs-placebo-plus-endocrine-therapy-for-hrher2-advanced-breast-cancer-a-phase-iii-rcts-based-meta-analysis","CDK4/6 inhibitors plus endocrine therapy vs. placebo plus endocrine therapy for HR+/HER2-advanced breast cancer: a phase III RCTs based meta-analysis","","Phase III RCTs-based evidence evaluates whether adding Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors to endocrine therapy (ET) improves outcomes in hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer. A systematic review and meta-analysis compared CDK4/6 inhibitors plus ET (CET) versus placebo plus ET (PET), assessing overall survival (OS), progression-free survival (PFS), response measures, and adverse effects (AEs).",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/cdk46-inhibitors-plus-endocrine-therapy-vs-placebo-plus-endocrine-therapy-for-hrher2-advanced-breast-cancer-a-phase-iii-rcts-based-meta-analysis/335138/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/cdk46-inhibitors-plus-endocrine-therapy-vs-placebo-plus-endocrine-therapy-for-hrher2-advanced-breast-cancer-a-phase-iii-rcts-based-meta-analysis/335138.png","ImageObject",300,407,{"name":42,"@type":43},"Ezra","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What clinical question does this meta-analysis address?","Question",{"text":63,"@type":64},"It evaluates whether combining CDK4/6 inhibitors with endocrine therapy improves survival outcomes and responses compared with placebo plus endocrine therapy in HR+/HER2-advanced breast cancer.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which endpoints are analyzed in the study?",{"text":68,"@type":64},"The primary endpoints are overall survival (OS) and progression-free survival (PFS), with secondary endpoints including responses and adverse events (AEs).",{"name":70,"@type":61,"acceptedAnswer":71},"What are the main benefits and risks of CET versus PET?",{"text":72,"@type":64},"CET shows significantly improved OS and PFS, along with higher response and clinical benefit rates. However, CET is associated with more total AEs, grade 3–5 AEs, and serious AEs, including hematologic toxicities.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},335138,1790169229,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":4},1099514068035,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Luo etal. BMC Cancer (2024) 24:1031 BMC Cancer  \n[https://doi.org/10.1186/s12885-024-12782-w](https://doi.org/10.1186/s12885-024-12782-w)  \nSYSTEMATIC REVIEW Open Access  \nCDK4/6 inhibitors plus endocrine therapy vs. placebo plus endocrine therapy for HR+/ HER2-advanced breast cancer: a phase IIIRCTs based meta-analysis  \nCailu Luo 1, Kunlin Yu 1, Xiaodan Luo 1, Tao Lian 1, Xuejuan Liu 1, Wang Xu 1 and Zhongkui Jin 1*  \nAbstract  \nBackground Does incorporating Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors into endocrine therapy (ET) effectively enhance survival outcomes, notably overall survival (OS), among individuals with hormone receptorpositive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer? This remains a clinical controversy. We compared the antitumor efficacy and adverse effects (AEs) between CDK4/6 inhibitors + ET (CET) and placebo + ET (PET) by conducting a phase III randomized controlled trials (RCTs) based meta-analysis. Methods Seven databases were searched to identify eligible studies, comprising Phase III RCTs comparing CET to PET. The primary endpoints were OS and progression-free survival (PFS), with secondary endpoints including responses and adverse events (AEs) .  \nResults Seven RCTs (DAWNA-2, MONALEESA-2, MONALEESA-3, MONALEESA-7, MONARCH-3, PALOMA-2, and PALOMA-4) were included. The CET group exhibited significantly improved OS (HR: 0.81 [0 . 74, 0 . 88]), PFS (HR: 0.57 [0 . 52, 0 . 63]), objective response rate (RR: 1.31 [1 . 20, 1.43]), and clinical benefit rate (RR: 1.11 [1 . 07, 1. 15]) . These benefits were consistent across almost all subgroups. Additionally, the CET group showed better overall survival rates (OSR) from 24 to 60 months (OSR 24–60 m) and progression-free survival rates (PFSR) from 6 to 60 months (PFSR 6–60 m) . However, more total AEs, grade 3–5 AEs, and serious AEs were found in CET group. The top 5 grade 3–5 AEs in the CET group were neutropenia (59 . 39%), leukopenia (24 . 11%), decreased white blood cell count (12 . 99%), hypertension (7 . 03%), and increased alanine aminotransferase (5 . 91%) .  \nConclusions The superiority of CET over PET in HR+/HER2-advanced breast cancer is evident, showing improved survival and responses. Nonetheless, the higher incidence of AEs, specifically hematologic AEs, requires cautious attention.  \nKeywords CDK4/6 inhibitors, Endocrine therapy, Breast Cancer, Meta-analysis, Randomized controlled trials  \n*Correspondence: Zhongkui Jin [jinzk1975@163.com](jinzk1975@163.com)  \n1Department of General Surgery, Yichun People’s Hospital, No. 1061 Jinxiu Avenue, Yiyang New District, Yichun, jiangxi 336000, China  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://](http://)[ ](http://)[creativecommons.org/l](creativecommons.org/l)icenses/by-nc-nd/4.0/.  \nLuo et al. BMC Cancer (2024) 24:1031  \nIntroduction  \nFor decades, breast cancer has been the most prevalent cancer worldwide, with approximately 2.26 million new cases diagnosed annually [1]. However, the fiveyear survival rate for ","cbCaitkaEAo5IhhE","https://ap.wps.com/l/cbCaitkaEAo5IhhE","pdf",5243738,14,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction\n# Materials and methods\n## Search strategy","[{\"question\":\"What clinical question does this meta-analysis address?\",\"answer\":\"It evaluates whether combining CDK4/6 inhibitors with endocrine therapy improves survival outcomes and responses compared with placebo plus endocrine therapy in HR+/HER2-advanced breast cancer.\"},{\"question\":\"Which endpoints are analyzed in the study?\",\"answer\":\"The primary endpoints are overall survival (OS) and progression-free survival (PFS), with secondary endpoints including responses and adverse events (AEs).\"},{\"question\":\"What are the main benefits and risks of CET versus PET?\",\"answer\":\"CET shows significantly improved OS and PFS, along with higher response and clinical benefit rates. However, CET is associated with more total AEs, grade 3–5 AEs, and serious AEs, including hematologic toxicities.\"}]","CDK4/6 inhibitors plus endocrine therapy vs. placebo plus endocrine therapy for HR+/HER2-advanced breast cancer: a phase III RCTs based meta-analysis | PDF",1790009775,35]